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Intraoral soft tissue masses can clinically present as benign, premalignant, or malignant 
lesions. Variability in presentation of soft tissue masses bear the possibility of misdiagnosis not 
only by general dentists but also by specialists. After a differential diagnosis is formulated, 
histopathologic evaluation is essential for establishing a definitive diagnosis. 
Neoplastic oral lesions in their early stages are subtle, which can make diagnosis 
challenging.  Dentists play a vital role in the prevention of oral malignancy by early detection, 
and a thorough understanding of the diagnostic features. However, as most intraoral pathology is 
benign, clinicians frequently do not include malignancy in their differential diagnosis for soft 
tissue masses.(1) The aim of this study is to emphasize the need for histologic diagnosis of 
seemingly benign soft oral lesions as the clinical impression may not be accurate.(2-6) 
We hypothesize that there will be a large number (~5%) of false negative diagnoses. 
These are cases in which the initial clinical diagnosis is a benign entity (e.g. fibroma or pyogenic 
granuloma) may change, upon histologic confirmation, to a pathologic diagnosis of a soft tissue 
malignancy.   We will also identify which clinical features (i.e. size, color, or clinical differential 
diagnoses) that were most commonly diagnostic pitfalls. The purpose of the study is to elucidate 
the features most commonly associated with malignancy.   
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1.0  BACKGROUND 
Intraoral soft tissue masses can clinically present as benign, premalignant, or malignant lesions. 
Variability in presentation of soft tissue masses create the possibility of misdiagnosis not only by 
general dentists but also by dental specialists. After a clinical differential diagnosis is formulated, 
histopathologic evaluation is essential for establishing a definitive diagnosis. 
Neoplastic oral lesions in their early stages are subtle, which can make diagnosis 
challenging.  Dentists play a vital role in the management of oral malignancy by the detection of 
premalignant lesions and early detection of cancer with routine head and neck examinations. 
However, as most intraoral pathology is benign, clinicians frequently do not include malignancy in 
their differential diagnosis for soft tissue masses.(1) The aim of this study is to emphasize the need 
for histologic diagnosis of seemingly benign soft oral lesions as the clinical impression may not be 
accurate.(2-6) 
We hypothesize that there will be a significant number (~5%) of false negative clinical 
diagnoses. These are cases in which the clinical impression is a benign entity (e.g. fibroma or 
pyogenic granuloma) but, upon histologic evaluation the pathologic diagnosis is of a malignant soft 
tissue mass.   We will also identify which clinical features (i.e. size, color, or clinical differential 
diagnoses) are most common diagnostic pitfalls. The purpose of the study is to elucidate the 
features most commonly associated with malignancy.   
Each year, in the United States, approximately 49,670 new oral cancers are diagnosed with 
9,700 estimated deaths, making oral cancer the sixth most common cause of cancer mortality.(7) 
The majority of oral cancers are squamous cell carcinoma (SCC) which accounts for over 95% of 
all oral malignancies. Premalignant dysplastic epithelial lesions precede oral SCC. Other less 
common malignancies are seen in the oral cavity. Lymphomas comprise 3% of oral tumors.(8)  
Sarcomas originate from mesenchymal cells and compose 1% of oral and maxillofacial 
malignancies.(4) Metastasis to the oral cavity is rare, accounting for 1% of all oral malignancies.(5, 
6) The rarity of these malignancies further increases the difficulty of diagnosis, with variable 
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clinical features associated with different malignancies. 
Malignant soft tissue masses in the oral cavity pose diagnostic difficulties. General dentists, 
who serve as the first line of patient contact, may not have substantial experience with oral cancer. 
The non-specific clinical presentation of these malignant masses may contribute to misdiagnosis, 
delayed, or improper treatment. The lesion may have a variable non-specific appearance as a flat 
white or red patch, an ulcer, or an exophytic mass.  Intraoral soft tissue masses can clinically 
present as benign, premalignant or malignant lesions. (1)  
Evidence suggests that routine examination for potential oral malignancies by trained health 
care providers will lead to diagnosis at a lower pathologic stage at diagnosis.(9)   Comprehensive 
oral examination, cervical lymph node palpation, as well as immediate referrals are essential 
components in early detection of malignancy, and reduction of mortality rates.(10, 11) Routine 
dental examination at time of bi-annual dental prophylaxis provides an opportunity to detect early 
asymptomatic cancer lesions.(9) Effective oral screening requires a knowledge of the risk factors, 
pathogenesis, and clinical behavior of malignant lesions. Upon identifying a lesion arising in the 
oral cavity, clinicians formulate a detailed description of the lesion, classifying it into the 
appropriate category based on salient features (e.g white lesion that is easily wiped off, red lesion, 
or an ulcer). Subsequently, based on the signs and symptoms and knowledge of the incidence of 
each entity, a prioritized differential diagnosis is created.(10) The priority ranking of differential 
diagnoses accounts for incidence, relative frequency, age, gender, race, and anatomical location of 
the lesion. 
We hypothesize that there will be a significant number of cases in which the clinical 
diagnosis is a common benign entity (e.g. fibroma or pyogenic granuloma) but, upon histologic 
evaluation the pathologic diagnosis is of malignancy.   
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1.1 SQUAMOUS CELL CARCINOMA 
Pain is one of the main presenting symptom in advanced stages of  oral SCC as  nerves or 
muscles are infiltrated, and it varies from mild to severe in intensity.(12) Therefore, early 
lesions are painless, asymptomatic, or associated with a vague discomfort, but not overt pain. 
However, tongue and floor of mouth lesions present with pain earlier.(12)  
An association between the primary tumor size and the existence of ulceration, 
bleeding and lymphadenopathy has been found. Central ulceration and ill-defined borders are 
observed in mature lesions.(13) Large oral malignant lesions are easier to diagnose than small 
lesions, misdiagnosis is associated with lesions presenting with seemingly innocent alterations 
such as color change or ulcers misdiagnosed as aphthae.(9) Ulcers in oral SCC manifest an 
irregular margin with elevation. 
SCC can range from few millimeters to several centimeters in size. Tumor thickness 
alters the clinical appearance of malignancies in the oral cavity. With time and growth of 
tumor, the gross morphology will show a thickened mucosa, or an exophytic mass.  Thick 
tumors are frequently ulcerated, with a low propensity of presenting erosions or plaques. 
Whereas, premalignant lesions are more likely to be thin.(14)  
Mortality is higher among lesions located in the retromolar trigone, and large tumors 
(T3-T4), as well as positive lymph nodes (N2a- N2b)(12). Early oral SCC mostly present as a 
relatively well-demarcated erythroleukoplakia, with slight surface roughness. In the anatomic 
location of the buccal mucosa and gingiva, tumors involving the tongue and retromolar trigone 
are associated with higher risk of cervical metastasis.(15) 
Soft tissue changes include loss of elasticity and induration upon palpation. Classic 
features of advanced stages include fixation to tissue, and induration. Other less common 
presentations include delayed healing after tooth extraction in an otherwise healthy individual, 
numbness of the chin, or a lump with increase vascularity.  
The oropharynx consists of the soft palate, lateral walls of pharynx, tonsils fossa, and 
the base of the tongue.(16) Clinically, oropharyngeal SCC presents with dysphagia, 
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odynophagia and otalgia.  The tissue structure and lymphatic drainage of the oropharynx, 
which is unique to this anatomic site, permits the malignant cells to more easily travel, 
resulting in a faster progression, with patients more commonly presenting with advanced 
tumor stage (III, or IV).(17) Human papilloma virus is the most significant factor in the 
prognosis of oropharyngeal SCC. The process of carcinogenesis is related to “viral 
oncoproteins, E6 and E7, which bind and inactivate tumor suppressors, p53 and pRb, 
respectively. Deficiency of p53 and Rb results in loss of cell cycle checkpoints and physiologic 
apoptosis.”(17)  Young men are mostly affected by HPV oropharyngeal SCC, and primary 
sites are small, if present, with increased nodal involvement.(17) Primary base of tongue 
lesion, tonsillar, or nasopharyngeal SCC present with a 5% rate of cervical lymph node 
involvement with no clinically apparent oral lesion.(12) HPV status of oropharyngeal SCC  is 
prognostically important, as patients have a 50% lower risk of death compared to HPV-
negative SCC.(18)  
While conventional SCC is the most common variant of SCC, other variants exist that 
are clinically relevant, including papillary SCC and verrucous carcinoma. Papillary SCC 
demonstrates an exophytic mass with a broad base attached to the mucosa, or a projected by a 
stalk. The finger-like projections dominate an infiltrative, endophytic growth.(16) Verrucous 
carcinoma is a slow growing tumor that appears clinically as a broad plaque that is distinct 
from the mucosa. It demonstrates a thickened texture with gray-white projections. Clinically, 
both of these variants of SCC behave more indolently, with verrucous carcinoma having a 
very low rate of metastases to the lymph nodes allowing surgeons to forgo neck 
dissection.(16) 
1.2 SALIVARY MALIGNANCY  
While most salivary pathology is benign, malignancies are more likely to arise as tumors in 
minor glands.(19)  Salivary gland tumors exhibiting rapid growth, pain and firmness prompt 
increased clinical consideration of a malignant lesion. Lack of pain is not always a sign of a 
benign entity.(20) Of the major salivary glands tumors, malignancy of the parotid gland is the 
most common.(21) Partial or complete facial nerve palsy, is an indicator of an infiltrating 
parotid gland malignancy.(22, 23) However, adenoid cystic carcinoma is seen mostly in minor 
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salivary glands. (19) The incidence of malignancies occurring in the minor salivary glands of 
the palate and submandibular gland are similar which are 40-60%. However, the incidence 
increases to 90 % in the tongue, floor of mouth, and sublingual glands.(24, 25)  
1.3 LYMPHOMA 
Representing 3% of oral malignancy, lymphoma is the third most common malignant tumor of 
the oral cavity after SCC, and salivary gland malignancies. Lymphomas of the oral cavity are 
present initially as an asymptomatic pink-blue, nodules or soft swelling with a predilection for 
the tonsils, palate and buccal mucosa. 50% of oral lymphomas may mimic infection as their 
first manifestation.(8)   However, if continued growth exerts pressure on adjacent tissue, 
including nerves, pain may develop. Lymphomas are difficult to identify clinically as it mimics 
periodontal diseases, and osteomyelitis. 50% of oral lymphoma may present as an infection as 
their first manifestation.(8) Since oral manifestations may appear as the first clinical evidence 
of lymphoma, an accurate detection is essential.  
1.4 ORAL METASTASIS.  
Oral metastases accounts for 1% of oral malignancies.(5, 6) In 30% of cases, oral metastasis is 
the initial presentation of underlying disease. Gnathic bone is more often involved than oral 
soft tissue. The gingiva and alveolar mucosa accounts for 54.8% of oral soft tissue metastases 
followed by the tongue in 27.4% of cases.(26) Metastases to the gingiva may resemble a 
reactive lesion such as pyogenic granuloma. Although oral metastasis can be a challenge to 
diagnose accurately, clinical signs may include a rapidly growing lesion, tendency to bleed, a 
necrotic appearance, or ulceration. Changes in the patient’s systemic health such as weight 
loss, fatigue, and malaise may be important signs and symptoms. Metastatic tumors to the oral 
tissue in males are mainly from the lung, kidney and prostate. In contrast, females exhibit 
breast, ovarian, and kidney metastatic tumors into the oral cavity.(27) 
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2.0  MATERIAL AND METHODS 
This is a retrospective study using data collected from the Oral Pathology Biopsy Service at the 
School of Dental Medicine, University of Pittsburgh. Cases of malignant soft tissue masses 
diagnosed between 1991 and 2016 are included. The patient demographics, anatomic site, 
clinical description, clinical history, risk factors, clinical impression of the dentist, and the 
histopathologic diagnosis rendered by the pathologists are recorded. This study is performed 
utilizing the Text Information Extraction System (TIES), a University of Pittsburgh Medical 
Center pathology database containing de-identified surgical pathology reports for retrieving 
data and identifying tissue. This system uses a natural language search strategy.    
 The inclusion criteria are all malignancies of the oral cavity diagnosed by the 
University of Pittsburgh Oral Pathology Biopsy Service including SCC, papillary SCC, 
lymphoma, salivary malignancy, sarcoma, and verrucous carcinoma. The exclusion criteria 
(420 cases) are cases without a clinical history, bone malignancies, non-malignant lesions 
(cases with the diagnosis of dysplasia, carcinoma-in-situ, or suspicious for SCC), and 
University of Pittsburgh Medical Center cases (rather than the University of Pittsburgh Oral 
Pathology Biopsy Service).  
Classification by location is performed; cases with malignancy of the lip, gingiva, hard 
palate, soft palate, buccal mucosa, floor of mouth, tongue, maxillary tuberosity, retromolar 
trigone, and mucosa of the alveolar ridge are identified and included. Cases involving 
intraosseous malignancy are excluded, as this was a study of soft tissue pathology.  
Histopathological reports and clinical information are analyzed for each case, 
information regarding demographic data (age, gender), risk factors (alcohol, tobacco), clinical 
history (duration, pain, bleeding, neuropathy, increase in size, tooth mobility, treatment, history 
of malignancy). The clinical appearance of the lesion such as (color, size, ulceration, texture) is 
recorded from the patients’ surgical pathology report.  
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Texture was divided into two categories (i.e. verrucous/papillary/roughened or smooth). 
Clinical density on palpation was divided into two categories (i.e. firm/hard/indurated or soft). 
The gross description including the size and shape of the specimen was recorded. The dentists’ 
clinical impression (1st and 2nd differential diagnosis) and the definitive histopathologic 
diagnosis are collected.  
2.1 STATISTICAL ANALYSIS 
The relation between clinicians’ misdiagnosis of the oral lesions and all recorded variables 
(gender, age, color, duration, increase in size, history of malignancy, ulceration, texture and 
site) was assessed using univariate logistic regression (see Table 1), odds ratio (OR), and 95% 
confidence interval were estimated.  Furthermore, a multivariable regression analysis (see 
Table 2) was performed to further explore the factors most affecting misdiagnosis. A reduced 
model (see Table 3) was conducted to analyze and remove statistically insignificant variables. 
All statistical analyses were conducted utilizing the STATA14 software. A P-value of <    0.05 
was considered significant. 
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3.0  RESULTS 
Our analysis of 25 years (1991-2016) of biopsies submitted by dentists for histologic 
examination supported our hypothesis of a high rate of false negatives exists (i.e. that clinicians identify 
oral soft tissue malignancy as benign clinical entities at a high rate).  
 
 
 
3.1 DEMOGRAPHIC FEATURES 
This study sample consists 485 oral malignancies with a 1.14 to 1 male to female ratio (258 
male, 226 female).  The mean and median patient age was 66 (22 to 90 range.) The majority of 
oral malignancies are observed in individuals 45 years- and older (see Figure 1). Univariate 
analysis showed that gender (male) and age (younger patients) have a statistically significant 
greater likelihood of the lesion being clinically misdiagnosed, with an odds ratio (1.56 (1.01-
2.41), 0.98 (0.97-1.00) and p-value (0.044, 0.047) respectively. See Table 1 for all 
variables assessed. 
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Figure 1. Summary of Demographic Data 
The above density histogram demonstrates the distribution of patients age in the 
sample. The data spread is from 22 to 90 years old with the peak of data occurring at 60 years 
old. The density represents the area of the bar; the sum of the areas of all bars is equal to 1. 
3.2 CLINICAL FEATURES 
The results of this study confirm that tumors with leukoplakia are associated with higher risk of 
misdiagnosis. It was found that leukoplakic tumors (white tumors) have a 2.4 odds of 
misdiagnosis compared to mixed (red-white) tumors. We found that the odds of misdiagnosing 
SCC with an erythroplakic (red) component is less by 4%. Less common clinical appearance, 
including lesions with colors such as tan, brown, blue, yellow and gray, have a 1.9 higher 
chance of being misdiagnosed.  
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The clinical duration in months, and clinical history of prior malignancy were 
statistically insignificant with a p-value of 0.577, and 0.134 respectively.  
The data confirmed that for every 1 cm increase in the size of oral tumor, the odds of 
misdiagnosis decrease by 43%, suggesting that smaller lesions were more likely to be missed. 
Therefore, clinicians tend to consider small lesions as being benign rather than malignant.  
We found a relationship between lack of ulceration and the risk of misdiagnosis. 
Clinicians are often thought to associate lesions presenting as a non-healing ulcer as potential 
malignancy, on the other hand, lesions lacking ulceration are thought to be benign in nature.   
Of 485 cases, 105 had a history of ulceration, 7 had no history of ulceration, and for the 
majority, 373 cases, 76.9%, this variable was not reported (see Table 1). Oral tumors with 
ulceration have a 67% reduced odds of misdiagnosis, suggesting that non-ulcerated lesions 
were likely to be missed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
Table 1. Univariate Analysis of Odds of SCC Misdiagnosis 
Variable Odds Ratio (95% CI) p-value 
Gender (female baseline) 1.56 (1.01-2.41) 0.044 
   
Age 0.98 (0.97-1.00) 0.047 
   
Color (baseline: mixed)  0.047 
Other 1.92 (0.85-4.33)  
Red 0.96 (0.45-2.05)  
White 2.42 (1.16-5.05)  
   
Duration (months) 1.01 (0.98-1.03) 0.577 
   
Increase in size (cm) 0.62 (0.47-0.82) 0.001 
   
History of malignancy 0.60 (0.31-1.17 0.134 
   
Ulcerated 0.36 (0.21-0.61) <0.001 
   
Verrucous 0.89 (0.28-2.82) 0.842 
   
Firm-hard-indurated 0.33 (0.12-0.96) 0.042 
   
Site (baseline: Buccal  0.44 
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Mucosa) 
Mandible 0.71 (0.23-2.15)  
Maxilla 0.47 (0.10-2.27)  
Other 0.55 (0.28-1.33)  
Palate 0.41 (0.09-1.94)  
Tongue 0.85 (0.35-2.08)  
 
 
 
Table 2. Odds of SCC Misdiagnosis Multivariable Analysis  
Variable Adjusted Odds Ratio  (95% CI) p-value 
Gender (female baseline) 1.97 ( 0.92-4.20) 0.080 
   
Age 0.97 (0.94-1.00) 0.044 
   
Color (baseline: mixed)  0.493 
    Other 1.44 (0.53-3.95)  
    Red 0.65 (0.24-1.77)  
    White 1.31 (0.52-3.30)  
   
Increase in size (cm) 0.62 (0.44-0.89) 0.008 
   
Ulcerated 0.25 (0.08-0.73) 0.011 
 
 
 
13 
 
Table 3. Odds of SCC Misdiagnosis Multivariable Analysis Reduced Model 
Variable Adjusted Odds Ratio (95% CI) p-value 
Gender (female baseline) 1.47 (0.82-2.65) 0.198 
   
Age 0.98 (0.96-1.00) 0.076 
   
Increase in size (cm) 0.57 (0.42-0.77) <0.001 
   
Ulcerated 0.33 (0.16-0.65) 0.002 
 
 
Among the recorded consistencies of oral lesions, clinically, the lesion was described as 
hard or indurated to palpation in 34 of 485 cases (451 cases had no data of this consistency).  
Lesions lacking this characteristic were less likely to be correctly clinically diagnosis (Odd 
ratio 0.33 (0.12-0.96), p=0.042.  
The most common anatomic sites presenting with a malignancy in descending order 
were tongue (32 %), floor of mouth (11 %), buccal mucosa (10 %), lip (9%), gingiva (8 %), 
mandible (8 %), palate (7 %), alveolar ridge (5 %), retromolar pad (4%), maxilla (4%), 
vestibule (1 %), pharynx (1%) (see Figure 2). 
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Figure 2. Distribution of Anatomic Site 
 
 
We observed a consistent significance in both size increase and ulcerated lesions 
following the multivariable model as well as the reduced model with the odds ratio of 0.57 
(0.42-0.77), 0.33 (0.16-0.65), and a p-value (<0.001, 0.002) respectively. 
Based on the factors in our model, there is a 71% chance we can differentiate between a 
random correct diagnosis and a random misdiagnosis (see Figure 3). 
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Figure 3. ROC Curve 
3.3 EXPOSURE TO RISK FACTORS 
Data on tobacco exposure was available for 142 patients, of these 3 had a history of previous 
tobacco usage, 86 were tobacco users, and 53 patients had no history of tobacco usage. 23 had 
a history of alcohol exposure with 113 having concomitant alcohol and tobacco risk factor.
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3.4 PATHOLOGIC DIAGNOSIS 
The most common oral malignancy was SCC (78.5%) with conventional SCC being most 
common (381/485 cases). Variants of SCC were less common, verrucous carcinoma accounted 
for 5.3 % of the lesions, and 3.2 % were papillary SCC, 1.6% were spindle cell SCC, and 0.4% 
were keratoacanthoma-type SCC.  5.7 % of the malignancies were salivary gland tumors. 3.2% 
were histologically diagnosed as lymphoma, 1.6 % were metastases to the oral cavity. Malignant 
melanoma of the oral cavity accounted for 0.6 % of lesions. 2% were categorized as other 
malignancies such as chondrosarcoma. 
 Our data demonstrated that 38% of SCC were clinically misdiagnosed. A benign clinical 
impression was considered in both primary and secondary clinical diagnosis. However, 29% of 
malignant lesions had a premalignant diagnosis of (epithelial dysplasia or epithelial atypia) in 
their clinical impression. Univariate results showed that gender (p-value 0.044), age (p-value 
0.047), color (p-value 0.047), increase in size (p-value 0.001), ulceration (p-value <0.001), 
and firm-hard-induced texture (p-value 0.042) are statistically significant.  
Many of the clinical impressions include benign entities (see Table 4). 
 
Table 4. Summary of Clinical Impressions 
Clinical impression  No. of cases Percent of total (485) 
Chronic inflammation  8 1.6 % 
Dysplasia  22 4.5 % 
Fibroma 17 3.5 % 
Actinic keratosis 3 0.6 % 
Epithelial Atypia 10 2.0 % 
 17 
Mucocele 6  1.2 % 
Lichen planus 9 1.8 % 
Granulation tissue  8 1.6 % 
Hyperkeratosis  17 3.5 % 
Papilloma 14 2.8 % 
Pleomorphic adenoma 6 1.2 % 
       Pyogenic granuloma 15 3.0 % 
TUGSE 7 1.4 % 
Ulcer 9 1.8 % 
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4.0  DISCUSSION 
Recognition of clinical features, signs, and symptoms of malignant lesions challenge clinicians in 
correctly detecting, diagnosing, and preventing the progression of oral malignancies. (28) Early 
malignant lesions of the oral mucosa are: asymptomatic; comprise a tendency toward 
maintaining their size; exhibit surface changes, and; show no response to treatments. With 
continued growth, oral tumors develop an exophytic growth adopting an irregular appearance, or 
demonstrating an endophytic growth that present frequently a dispirited ulcer showing a raised, 
and everted border.(29) 
Our study finds that oral malignancy was not correctly clinically identified in cases with a 
small anatomic size of the lesion (e.g. lesions less than 0.5 cm in size).  Clinically, tumor size is 
the greatest surface dimension of the lesion. Pathologically, it is the greatest diameter of the 
specimen. (30) The maximum dimension and correlated lymph node metastasis of 155 oral SCCs 
were analyzed. It was concluded that tumors of 2 cm and smaller demonstrated metastasis to 
lymph nodes, with a good prognosis. In malignant tumors measuring more than 2 cm, the growth 
in size is not associated with an increased risk of nodal metastasis, except in large tumors that 
demonstrate infiltration. (31) Rate of metastases in oral SCC is mainly dependent on tumor size 
and differentiation. T1 and T2 are associated with high metastases. (32),(15) In the tumor-node-
metastasis (TNM) clinical staging system (where T is the size of the primary tumor, N is the 
involvement of regional lymph node, and M is distant metastasis) , T is a prognostic factor for 
survival. (34) A study showed that T3/T4 classification are associated with a significantly higher 
rate of mortality. (33) Smaller tumor size does not exclude the presence of SCC but it may be 
clinically asymptomatic in early stages. Oral SCCs can range from few millimeters to a number 
of centimeters at presentation. In a series of 102 asymptomatic oral SCCs, 17% of SCCs were 
reported to be less than 2 cm. (34)  Large malignant lesions imply lymph node metastasis, and 
raise the incidence of local failure.(35) Specifically, tumor thickness or depth has been a 
 19 
significant indicator of subclinical lymph node metastasis and a prognostic factor. A 3-mm thick 
tumor has 8% nodal metastasis, 0% recurrence, and 100% 5-year survival. Tumors that are more 
than 3-mm to 9-mm thick have a 44% rate of nodal metastasis, 7% recurrence, and 76% 5-year 
survival.(36) Our data demonstrates that clinician's struggle in diagnoses most in lesions less 
than 0.5cm. 
Interestingly, our data suggests that men are more likely to be misdiagnosed. Oral cancers 
are high among men compared to female. (37), (38), (39) It is well established in the literature 
(40), (41) that male patients are less likely to seek medical care. Male patients’ health behavior 
includes poor oral hygiene and fear of physicians, young males are more likely associated with 
smoking and extreme alcohol consumption. (42)  Males have a known increased risk for oral 
cancer (37), (38), (39) but we hypothesize on presentation, they may minimize their symptoms 
by less expression of symptoms to care providers.   Perhaps due to a greater risk of malignancies 
seen in male population, male patients with SCC are seen by dental practitioners earlier age than 
women (38) which may result in presenting with early lesions.  Conversely, female patients may 
be more vocal about clinical symptoms, whereas male patients minimize these symptoms. 
As might be expected; our data suggest oral SCC in young individuals are prone to be 
misdiagnosed by clinicians. However, due to a higher incidence of HPV driven oropharyngeal 
SCC, younger individuals carry a higher risk of distant metastasis. It is well established that HPV 
related oropharyngeal SCC presents in a younger patient population than conventional SCC. 
Young females have a higher proportion of recurrence rate of tongue cancer. (43) Thus, as the 
demographics of SCC shift (because of the epidemic of HPV driven oropharyngeal SCC), 
clinicians must be aware of the increasing incidence in younger patients. SCC has a wide range 
of presentation with a myriad of risk factors. Many dental practitioners are more familiar with 
conventional SCC and its risk factors, only in the last decade or two has the increase in HPV 
related SCC come to the forefront. Newer studies on SCC in young individuals (<45 years old) 
show a mean age of 32.5 with a male predilection, and tongue predisposition. (44)  It is 
suggested that young patients diagnosed with oral SCC possess a more aggressive, and higher-
grade tumor when compared to old patients. However, younger patients exhibit a significantly 
higher survival rate. 
The most established feature of oral SCC is the presence of ulceration (12) as non-healing 
ulcers are frequently seen with oral SCC. However, the presence of an ulcer is not among the 
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initial signs of a developing SCC. (45) Our data showed that lesions lacking an ulcer had a 
greater chance of misdiagnosis, if clinicians assume that oral SCCs usually present with non-
healing ulceration.  A superficial ulcer is seen in a more advanced cancer, its features usually 
include irregular floor with slight raised margins, and with time, firmness to palpation is 
encountered. (12) If an ulcer occurs on the vermilion border it is frequently concealed with a 
crust. (46) The most common oral mucosal site for ulcers are the lower lip, the tongue, and the 
floor of mouth.(46) In our study, 1.6 % of malignant lesions had traumatic ulcer in their 
differential diagnosis. Clinicians are required to ensure the resolution of ulcers malignancy is in 
the differential. (47) SCC in the micro-invasive stage is an early thin tumor that does not invade 
deep tissue. Micro-invasive tumors carry unique characteristics, they are featured regularly as 
patches or erosions rather than discrete ulcers.(14)  
Early SCCs frequently arises as red, white, or mixed lesions. As the lesion progress an 
ulcer is developed. With more time, a fungating mass grows, or an endophytic growth is shown 
featuring a rolled, raised border.(48) One of the features of SCCs developing in the oral cavity is 
the change in the color of the mucosa. Leukoplakia is defined by the World Health Organization 
as “a white patch or plaque that cannot be characterized clinically or pathologically as any other 
disease.(49)” Therefore, leukoplakia is a clinical term and is not utilized as a microscopic 
diagnosis.(50) The term leukoplakia is under constant improvement. White patches that are 
secondary to local irritation rarely demonstrate dysplastic changes or malignant transformation. 
Such as hyperkeratotic lesions on edentulous alveolar ridges are usually a protective, reactive 
phenomenon.(51) Likewise, morsiactio buccarum or morsicatio linguarum that evolve from 
chronic check or tongue biting should be categorized separately as they are not premalignant 
lesions, thus, should not be considered as leukoplakia.(48)  Leukoplakia remains a suspicious 
lesion and require a conventional biopsy. Even non-carcinomatous leukoplakia may harbor a 
future malignancy. The malignant transformation in oral leukoplakia ranges from 15.6 % to 
39.2%. (50, 52-54) Similarly, erythroplakia is a red patch which cannot be diagnosed clinically 
as any other lesion(49).    
Erythroplakia showed higher tendency toward carcinoma. In 65 cases of erythroplakia, 
all exhibited dysplasia, and 51% presented with invasive SCC.(48) Although leukoplakic lesions 
are more common, erythroplakia are more worrisome. The most common oral locations affected 
by erythroplakia are the floor of mouth, soft palate, retromolar trigone, and the lateral surface of 
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the tongue. Clinicians recognize that erythroplakic lesions are high risk lesions and a greater 
likelihood of correct diagnosis were associated with red lesions with OR 0.96 (0.45-2.05).  
As the duration of the oral lesion had no effect on the clinical diagnosis in this study. We 
found the average length of duration of malignant lesions is 7.75 months which indicates the 
necessity to educate patients regarding the added value of oral cancer screening as a component 
of periodic oral examination in conjunction with dental prophylaxis. Delays in the diagnosis of 
oral malignancies from the time of recognition of symptoms to the onset of professional 
diagnosis is frequent. The asymptomatic early SCC attribute to delay in diagnosis. A median of 
30 of days is the time until clinical diagnosis of oral malignancies with a range of 14 days to 2 
years.(55, 56) Age is not a contributing factor to diagnostic delay.(55-58) Lethal delays are 
associated with clinical evaluation that are not referred to follow-up for investigation.(59) 
 Although a malignant neoplasm in the patients’ medical history had little impact on the 
accuracy of clinicians’ differential diagnosis in this study, a prevalence of 10% to 24 % 
development of second malignancy tumors following a primary cancer(60-63), and 8.0 % 
incidence rate of a secondary neoplasm arising within 10 years after the primary tumor (64), with 
a lower 5-year survival rate. Our study comprised 13 % of patients with a complain of a previous 
malignant neoplasm from variable sites within the body such as the lung, larynx, esophagus, 
colon, breast, prostate, and liver. Past malignancy of the oral, head and neck region accounted for 
2.6%.  
 Texture and consistency of oral lesions is one of the essential parameters to consider 
during diagnosis. Lesions of the oral mucosa presenting with non-homogeneous texture warrant 
precancerous dysplastic changes. Homogenous lesions present on the floor of mouth and tongue 
exhibit a higher rate of dysplastic changes. (65) Firmness is among the strong indicators of oral 
malignancies, when firmness is increased upon palpation, infiltration is considered. 
  Studies regarding the association between risk factors (i.e. tobacco and alcohol 
consumption) and oral SCC are well established.(66, 67) Yet, in our oral pathology reports that 
are obtained from the clinicians, most commonly Oral and Maxillofacial surgeons, the history of 
smoking and alcohol was often not included as either a pertinent positive or negative factor.  
 Consistent with previous studies(48, 68, 69), the tongue and floor of mouth in our study 
represented the most common anatomic sites (32%, 11%) respectively. All oral mucosa is 
susceptible to the development of cancer, but some areas bear a higher risk of malignancy. 
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Interestingly, the site of the originating tumor was disregarded by clinicians even though it is 
well known that the floor of mouth and tongue possess a greater malignant potential due to 
factors such as the histology of these areas; comprising a thin, non-keratinized epithelium which 
minimally protects against carcinogens, and; the presence of carcinogens within the saliva which 
stay for long periods in the floor of the mouth and  can have harmful effects(70).  
 The association between the location of the neoplasm and survival depends upon lymph 
node metastasis.(43) Malignant neoplasms of the tongue are more likely to metastasis compared 
to gingival and buccal tumors.(15)  Approximately 55 % to 70 % of SCCs presenting in the 
tongue, occur between the middle and posterior thirds of the lateral border.(71, 72) SCC of the 
base of tongue accounts for one third of tongue SCCs, and less likely to present with symptoms, 
thus, usually present with more advanced stage at the time of diagnosis.(72, 73)   Primary tumors 
of the tongue accounts for 66% of neck metastasis at the initial time of diagnosis due to its 
extensive blood support and lymphatic drainage.(74)  Malignant lesions occurring in the 
retromolar area, posterior buccal mucosa, and hard palate raise the possibility of invading the 
anatomically complex masticator space.(43) Limited margins resection and rapid failure are 
observed in individuals diagnosed with stage T4b oral cancer which have poor prognosis. 
However, patients with negative cervical lymph node metastasis, or one positive lymph node 
metastasis without nerve invasion will demonstrate positive outcomes from surgery, as well as 
patients diagnosed with a malignancy located underneath the mandibular notch.(43) 
In this study, the gingiva accounted for 8% of tumors.  Malignancies of the gingiva have 
been studied in depth. In a study investigating the clinical and histologic appearance of SCC of 
the gingiva in 519 cases, it was reported that the majority of lesions were present in the posterior 
mandibular gingiva (69%).(75) The duration until the onset of diagnosis was less than 6 weeks in 
75% of cases compared to floor of mouth and tongue SCC.(75) The most frequent symptom in 
gingival SCC is a mass-like lesion as well as ulceration. Diagnosis delay in gingival SCC is very 
common due to the similarity to benign lesions such as gingival inflammatory growth.(75) In 
13% of cases, tooth extraction is an identifying gingival SCC. Atypical periodontal disease, or 
aggressive appearing gingival lesion also evoke the possibility of malignancy. (75) Tumors of 
the buccal mucosa are frequently associated with the utilization of tobacco products. SCC of the 
buccal area bear a poor prognosis and show recurrence within 1-2 years.(76)  
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The different parameters that play a role in the identification process of malignant tumors 
(e.g. loosening of teeth, bleeding, and pain) can be related to misdiagnosis, however, the low 
sample size due to missing data in these variables, prevented us from including it in the 
regression model, thus, analyses of these variables should be further investigated. 
 Non-palpable, asymptomatic carcinomas with negative lymphadenopathy remain 
ambiguous to diagnose but with intensifying sites at high risk, and acknowledging early 
presentations of oral SCC this will contribute to early diagnosis. (77)   
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5.0  CONCLUSION 
Our results support our hypothesis.   We have found that a majority of oral malignancies, 
especially SCCs, were clinically misdiagnosed.  Clinical misdiagnosis is significantly associated 
with male gender, young individuals, smaller size neoplasms, and lack of ulceration. Although 
factors such as a history of malignancy, tobacco and alcohol use, and the location of the tumor 
had a minor influence on clinical diagnosis in this study, these factors are highly associated with 
increasing risk of oral malignancies.  
Early detection of malignant signs impact overall prognosis. Dentists play a vital role in 
the prevention of oral malignancy by early detection, and a thorough understanding of the 
diagnostic features. They are “first line of defense” for both the symptomatic and asymptomatic 
signs of cancer(78-80). While clinicians perform well-established screening practices, most 
intraoral pathology is benign, and it is advisable for clinicians to include malignancy in their 
differential diagnosis for soft tissue masses. Clinicians are also advised to correlate between 
clinical and histological diagnosis. (81, 82)  Our data suggest that this is especially true for small 
lesions in younger patients, where the risk of malignant potential  may not be considered.  
 While clinical impression is important, histologic diagnosis is the gold standard for 
providing care for patients. 
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